01.29.2019 Issue 436

   
Visit HealthEconomics.Com Subscribe to Newsletters  |  Contact Us  |  Forward to a Friend
Sponsored by:

This Week's HEOR Round-up
The Top Story in HEOR: Latest Headlines in HEOR:

Eli Lilly Explains How it Handled
Price Information in New TV Ads

Saturday, January 26

Drugmaker Eli Lilly recently discussed with MM&M how it developed its marketing strategy for its first advertisement with pricing details for its diabetes treatment, Trulicity.

Podcast Highlights 2018 Value-Based Care Summit

ISPOR Publication Synthesizes 'Good Practices' in HTA

Dimon: U.S. has Best System, Worst Outcomes

Bloomberg Analysis: PBMs Got Major Markup in New York

Report: Insulin Price Hikes Cause Diabetes Costs to Surge

The ‘Netflix Model’ for Drug Pricing


Researcher-Safety & Epidemiology-PS16647

Researcher-Safety & Epidemiology-PS16646

Health Economics Analyst / Statistician

Health Economics Consultant

Industry Spotlight


Conferences Webinars
2nd Annual Provider Strategies on Community Partnerships and Social Determinants of Health Track
    January 30-February 1, Atlanta, Georgia

Patient Registries and Real-World Evidence
    January 30-31, Miami, Florida

Investigator Initiated Sponsored Research Summit
    February 6-7, Cambridge, Massachusetts

Statistical Learning: What Is It? How Does It Relate to Machine Learning and AI? How is It Applied in Healthcare?
    January 30

Let’s Get Real: How Will the FDA Framework for Real-World Evidence Impact You?
    January 30


Conference of the Week Webinar of the Week Job of the Week Link of the Week

Syndicated Reports White Papers
Innovative Drugs: Mapping the Pricing and Reimbursement Landscape

Orphan Drugs: European Payer Perspectives

Do Payers Really Want Pay-for-Performance?

Payer Engagement: Benchmarking Team Structure and Activity

Benchmarking Market Access Strategies for High-Cost Drugs, Biologics

Blockchain: Transformational Change for Pharma?

HTA in Europe: Key Success Factors for Positive HTA Recommendations

Breaking Through the Hype of Real-World Evidence

Time to Market: Accelerating Market Access

Orphan Drugs in the United States

Charting Real World Data and Evidence – Activity and Capabilities (2018)

From Patent to Patient: Analyzing Access to Innovative Cancer Drugs

Transitioning Payment Models: Fee-for-Service to Value-Based Care


 
Special Thanks to Our Partners:
               Evidera   HealthCore  
      University of FL   Xcenda  OM1    Parexel   Jefferson
      Dymaxium   Precision Xtract    Pharmerit    eMax Health
      Sciformix   Evidence Partners    ICON    Truven
Share this newsletter on social media:

Email Twitter Facebook LinkedIn